Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma group ...
The Federal Reserve has already lowered rates twice in 2025, but with just one meeting left before the new year, consumers are eager to learn if there will be another cut. Following a series of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback